<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300078</url>
  </required_header>
  <id_info>
    <org_study_id>MF101-008</org_study_id>
    <nct_id>NCT01300078</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Assessing Safety of MF101 for Hot Flushes</brief_title>
  <official_title>A Phase 1 Open Label, Randomized Clinical Trial Assessing Safety of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionovo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy,
      postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses
      of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United
      States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MF101 is an oral, non-hormonal, botanical agent being investigated for the treatment of
      menopausal hot flashes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety of MF101, 10 g/day and 15 g/day</measure>
    <time_frame>Randomization to 4 weeks</time_frame>
    <description>New or worsening abnormalities on breast, physical and general exams, laboratory measures, transvaginal ultrasound, abnormal uterine bleeding, adverse events and serious adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the safety of MF101 10g/day and 15 g/day</measure>
    <time_frame>Randomization to 4 Weeks</time_frame>
    <description>To compare the safety of the 2 doses of MF101</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>MF101 10 grams/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF101 15 grams/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF101</intervention_name>
    <description>MF101 10 g/day MF101 15 g/day</description>
    <arm_group_label>MF101 10 grams/day</arm_group_label>
    <arm_group_label>MF101 15 grams/day</arm_group_label>
    <other_name>Menerba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (partial list):

          -  Postmenopausal women aged 40-65 years.

          -  Provide informed consent.

          -  Currently receive medical care from a health care provider. Other inclusions apply.

        Exclusion Criteria (partial list):

          -  History of malignancy other than non-melanoma skin cancer or cervical cancer that was
             diagnosed and fully treated less than 5 years before screening.

          -  Unexplained uterine bleeding within 6 months prior to Screening.

          -  History of deep vein thrombosis or pulmonary embolism.

          -  Active liver disease or a history of impaired.

          -  Active gallbladder disease. Other exclusions apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wulf Utian, PhD, DSc(Med), FRCOG, FACOG</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates, Jordan Research and Education Institute (REDI)</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mary Tagliaferri, MD, LAc/President and CMO</name_title>
    <organization>Bionovo</organization>
  </responsible_party>
  <keyword>Hot Flashes</keyword>
  <keyword>Hot Flushes</keyword>
  <keyword>Vasomotor Symptoms</keyword>
  <keyword>Menopausal Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

